VIA EDGAR AND ELECTRONIC MAIL
GT
BIOPHARMA, INC.
9350
Wilshire Blvd. Suite 203
Beverly
Hills, CA 90212
July
24, 2020
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100 F
Street, N.E.
Washington,
D.C. 20549
RE: GT
Biopharma, Inc.
Registration
Statement on Form S-1 (File No. 333-239858)
Request
for Acceleration of Effective Date
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the Securities Act of 1933, as amended, GT
Biopharma, Inc. hereby respectfully requests that the Securities
and Exchange Commission accelerate the effective date of the
above-referenced Registration Statement on Form S-1 (File No.
333-239858) and declare the Registration Statement effective as of
July 28, 2020, at 4:00 p.m. (Eastern time), or as soon as
practicable thereafter.
Please
contact the undersigned at (800) 304-9888, or Michael Hamilton,
Baker & McKenzie LLP, at (713) 427-5033, with any questions.
Also, please notify Mr. Hamilton by telephone when this request for
acceleration has been granted.
|
|
Very
truly yours,
|
|
|
|
|
|
GT
Biopharma, Inc.
|
|
|
|
|
|
|
|
|
By: /s/
Steven Weldon
|
|
|
Name:
Steve Weldon
|
|
|
Title:
Chief Financial Officer
|